Mariusz A Wasik Selected Research

Non-Receptor Type 6 Protein Tyrosine Phosphatase

3/2007	Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
5/2005	STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.
11/2002	Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mariusz A Wasik Research Topics

Disease

36	Neoplasms (Cancer) 01/2022 - 01/2002
25	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2019 - 11/2002
15	Lymphoma (Lymphomas) 03/2021 - 01/2002
13	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 05/2005
9	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2013 - 05/2002
7	Carcinogenesis 01/2022 - 12/2005
6	Leukemia 10/2020 - 04/2006
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2019 - 09/2006
4	B-Cell Lymphoma (Lymphoma, B Cell) 03/2021 - 12/2002
4	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2017 - 12/2002
4	Inflammation (Inflammations) 12/2014 - 06/2011
3	Burkitt Lymphoma (Burkitt's Lymphoma) 03/2021 - 08/2009
3	Mycosis Fungoides 12/2014 - 04/2013
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/2021 - 08/2009
2	Hypoxia (Hypoxemia) 10/2020 - 01/2017
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2017 - 09/2003
2	Starvation 07/2016 - 09/2006
2	Disease Progression 08/2013 - 04/2013
2	Dermatitis 08/2013 - 11/2011
2	Infections 09/2011 - 02/2005
2	Sezary Syndrome (Sezary Erythroderma) 06/2008 - 01/2002
1	Residual Neoplasm 01/2021
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Cytokine Release Syndrome 12/2017
1	Hodgkin Disease (Hodgkin's Disease) 10/2017
1	Genetic Translocation (Chromosomal Translocation) 01/2017
1	Hypersensitivity (Allergy) 01/2017
1	Melanoma (Melanoma, Malignant) 01/2016

Drug/Important Bio-Agent (IBA)

14	Anaplastic Lymphoma KinaseIBA 01/2022 - 01/2002
13	CytokinesIBA 01/2019 - 02/2008
11	Phosphotransferases (Kinase)IBA 01/2022 - 12/2005
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2002
6	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 01/2002
6	Interleukin-2 (IL2)IBA 07/2016 - 11/2002
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 04/2006
5	MicroRNAs (MicroRNA)IBA 01/2018 - 11/2011
4	NucleophosminIBA 01/2022 - 04/2009
4	Transforming Growth Factor beta (TGF-beta)IBA 10/2020 - 01/2002
4	Chimeric Antigen ReceptorsIBA 12/2017 - 01/2016
4	Interleukin-17 (Interleukin 17)IBA 03/2016 - 06/2011
4	Mechanistic Target of Rapamycin Complex 1IBA 12/2013 - 02/2008
3	Tyrosine Kinase InhibitorsIBA 01/2018 - 05/2013
3	p80(NPM-ALK) proteinIBA 01/2017 - 04/2009
3	AntibodiesIBA 01/2016 - 03/2003
3	TOR Serine-Threonine KinasesIBA 01/2016 - 05/2003
3	Messenger RNA (mRNA)IBA 06/2015 - 12/2008
3	Membrane Proteins (Integral Membrane Proteins)IBA 03/2014 - 12/2008
3	Interleukin-15 (Interleukin 15)IBA 01/2014 - 02/2008
3	Interleukin-10 (Interleukin 10)IBA 12/2013 - 06/2006
3	interleukin-21 (interleukin 21)IBA 02/2009 - 02/2008
3	Non-Receptor Type 6 Protein Tyrosine PhosphataseIBA 03/2007 - 11/2002
2	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 10/2020 - 01/2002
2	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 10/2020 - 01/2017
2	EnzymesIBA 05/2020 - 01/2013
2	Agammaglobulinaemia Tyrosine KinaseIBA 10/2019 - 01/2019
2	ibrutinibIBA 01/2019 - 01/2016
2	olaparibIBA 01/2018 - 01/2017
2	talazoparibIBA 01/2018 - 01/2017
2	Therapeutic UsesIBA 01/2017 - 02/2009
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2017 - 09/2003
2	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 01/2013
2	tisagenlecleucelIBA 01/2016 - 01/2016
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2016 - 01/2013
2	Enterotoxins (Enterotoxin)IBA 07/2014 - 04/2007
2	Bacterial ToxinsIBA 08/2013 - 04/2007
2	Sirolimus (Rapamycin)FDA Link 01/2013 - 01/2011
2	Interferon Type IIBA 09/2011 - 02/2009
2	Bexarotene (LGD1069)FDA Link 10/2008 - 08/2005
2	RetinoidsIBA 10/2008 - 08/2005
2	Complementary DNA (cDNA)IBA 04/2006 - 01/2002
2	Tyrosine (L-Tyrosine)FDA Link 12/2005 - 11/2002
1	Immune Checkpoint ProteinsIBA 03/2021
1	Acetyl Coenzyme A (Acetyl-CoA)IBA 05/2020
1	src-Family KinasesIBA 05/2020
1	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2020
1	ATP Citrate (pro-S)-Lyase (Citrate Synthase, ATP)IBA 05/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2018
1	fms-Like Tyrosine Kinase 3IBA 01/2018
1	ElementsIBA 01/2017
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2017
1	Staphylococcal enterotoxin AIBA 03/2016
1	PentosesIBA 01/2016
1	GlycogenIBA 01/2016
1	ponatinibIBA 01/2016
1	diphosphoric acid (pyrophosphoric acid)IBA 01/2016
1	Glutamic Acid (Glutamate)FDA Link 01/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2016
1	malic acid (malate)IBA 01/2016
1	Adenosine Triphosphate (ATP)IBA 01/2016
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2016
1	Imatinib Mesylate (Gleevec)FDA Link 01/2016
1	Pyruvic Acid (Pyruvate)IBA 01/2016

Therapy/Procedure

12	Therapeutics 01/2021 - 02/2005
2	Drug Therapy (Chemotherapy) 01/2017 - 08/2004
2	Immunotherapy 01/2016 - 02/2009
2	Transplantation 12/2010 - 04/2006
2	Organ Transplantation 08/2005 - 05/2002
1	Precision Medicine 10/2017